NCT07644585
A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck
Not Yet Recruiting
NAAges 18+InterventionalTreatmentIBA Proton Therapy, Inc.
~10 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:ConformalFLASH irradiation
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
ConformalFLASH treatment delivery feasibility
Measured over Through treatment completion (within 1 month after last fraction)
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Alexander Lin, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- ConformalFLASH treatment delivery feasibilityThrough treatment completion (within 1 month after last fraction)
Delivery of ≥ 95% of the prescribed dose to ≥ 95% of the clinical target volume (CTV) at an average dose rate of ≥ 40 GyRBE/second
- Acute toxicitiesUp to 3 months after treatment start
Incidence of acute toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 6.0